Rebate Management for Hospitals & Health Systems
Drug spend in hospital environments runs through purchasing, pharmacy, billing, and finance — each with a partial view of what's happening. VativoRx brings a unified rebate process across inpatient and outpatient settings without requiring any of those teams to change how they operate.
Schedule a Discovery Call →Where Hospital Complexity Creates Gaps
Hospitals don't have a rebate problem. They have a coordination problem. Inpatient pharmacy, outpatient clinics, GPO contracts, 340B eligibility, and billing workflows each carry different rules and different stakeholders.
When rebate activity is reviewed, it often happens in pieces — by department, by claim type, by vendor — rather than as a unified picture. The result is inconsistent visibility across the organization and a harder time explaining rebate performance to finance and compliance leadership.
Most hospital finance teams can't tell you what their rebate picture looks like. Not because the data doesn't exist — because no single process is connecting it.
What a First Review Typically Surfaces
For an acute care health system with no prior rebate management process in place, the first structured review established a baseline picture of eligibility across both inpatient and outpatient drug spend — for the first time.
The engagement identified a meaningful volume of rebate-eligible claims across specialty and acute care therapies that had not previously been captured through existing vendor relationships or billing workflows.
How VativoRx Supports Health Systems
VativoRx connects those environments under a single structured review process — one that covers inpatient and outpatient drug spend together, accounts for GPO and 340B structures from the start, and produces reporting each functional team can use without a custom request.
What This Helps You See
- A unified view of rebate activity across inpatient and outpatient claim environments — not pieced together by department
- A clear audit trail showing which claims were eligible, which were excluded, and why — available for internal review at any point
- Cleaner internal alignment — finance, pharmacy, compliance, and leadership working from the same rebate picture rather than reconciling different vendor outputs
- Which areas of drug spend have rebate exposure that no existing vendor or workflow is currently capturing
Practical to Evaluate
From first conversation to a clear picture of your drug spend — without disrupting a single team or workflow.
- Discovery call — 15 minutes to understand your claim environment, purchasing structures, and current rebate visibility
- Scope definition — we define what data is needed and in what format. No PHI, no EMR access required
- Phase 1 analysis — inpatient and outpatient covered under one process, delivered on a defined timeline
- Decision point — expand scope, continue, or conclude based on findings. Not a default contract extension
Most health system engagements reach Phase 1 analysis within 1–2 weeks of initial data transfer.